Bayer Ag · XETR:BAYN

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023

10 slides from Bayer's conference presentation, Oct 5, 2023

  1. Slide 1: Intravitreal Aflibercept 8 mg in Patients with PCV: A Phase 3 PULSAR Trial Subgroup Analysis

    Intravitreal Aflibercept 8 mg in Patients with Polypoidal Choroidal Vasculopathy (PCV): A Phase 3 PULSAR Trial Subgroup Analysis Chui Ming Gemmy Cheung,1 Tien Y Wong,2 Jeffrey S Heier,3 Xin Zhang,4 Tobias Machewitz,5 Andrea Schulze,5 Sergio Leal,4 on behalf of the PULSAR study investigators 1Duke-NU

  2. Slide 2: Disclosures

    Disclosures nAMD • CMGC: received consultant fees, speaker fees, and grant funding from Avirmax, Bayer, Boehringer Ingelheim, Janssen, Novartis, Roche, Topcon, and Zeiss o TYW: Consultant fees from Aldropika Therapeutics, Bayer, Boehringer Ingelheim, Genetech, Iveric Bio, Novartis, Oxurion, Plano, R

  3. Slide 3: PULSAR Study Design and Dosing Schedule

    PULSAR Study Design and Dosing Schedule nAMD

  4. Slide 4: PCV in PULSAR

    PCV in PULSAR * PULSAR is a global study conducted across 223 sites in 27 countries * ICGA was optional and conducted in 295 patients in 12 countries? * PCV present, n=139; PCV absent, n=153 * Data missing, n=3 reported 0.7% (n=1) Asian (n=41) 69.8% (n=97) PCV subgroup (ICGA-confirmed) 2q8 All 8 mg

  5. Slide 5: PCV Subgroup: Absolute and Change from Baseline in BCVA through Week 48 (LOCF)

    PCV Subgroup: Absolute and Change from Baseline in BCVA through Week 48 (LOCF) nAMD

  6. Slide 6: PCV Subgroup: Proportions of Patients Maintained on Q12 and Q16 Dosing Intervals through Week 48

    PCV Subgroup: Proportions of Patients Maintained on Q12 and Q16 Dosing Intervals through Week 48 nAMD

  7. Slide 7: PCV Subgroup: Anatomic Endpoints

    PCV Subgroup: Anatomic Endpoints nAMD

  8. Slide 8: PCV Subgroup: Additional Analyses

    PCV Subgroup: Additional Analyses nAMD

  9. Slide 9: PCV Subgroup: Safety – Week 48

    PCV Subgroup: Safety – Week 48 nAMD Data are from the SAF. TEAEs are AEs occurring from the first injection to 30 days after the last injection (active or sham); ocular TEAEs are those occurring in the study eye. aData presented in this way to avoid unintentional patient unmasking. AE, adverse event

  10. Slide 10: Conclusions: Aflibercept 8 mg Monotherapy in PCV

    Conclusions: Aflibercept 8 mg Monotherapy in PCV nAMD

Bayer — 23rd European Society of Retina Specialists (EURETINA) Congress 2023 on 6ix